{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["27(Suppl 2)"],"submitter":["Vincent P"],"journal":["Annals of oncology : official journal of the European Society for Medical Oncology"],"pagination":["ii83-ii84"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4984073"],"repository":["biostudies-literature"],"pubmed_title":["P-286Metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel (nab-P), bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer (MPC): an open-label, multicenter, single-arm, phase 1/2 study"],"pmcid":["PMC4984073"],"pubmed_authors":["Vaibhav S","Wasif S","Philip P","Diane S","Aparna K","Caio R","Allyson O","Victoria M","Vincent P","Michael O","Jack S"],"additional_accession":[]},"is_claimable":false,"name":"P-286Metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel (nab-P), bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer (MPC): an open-label, multicenter, single-arm, phase 1/2 study","description":null,"dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Jun","modification":"2025-04-26T20:35:11.766Z","creation":"2025-04-06T16:26:33.942Z"},"accession":"S-EPMC4984073","cross_references":{}}